Expression of REV1 in the non-small cell lung cancer cell lines was significantly positively correlated with log(IC50) of MEK (mitogen-activated protein kinase) inhibitors PD-0325901, RDEA119, and trametinib, as well as AKT inhibitor VIII, XIAP inhibitor embelin, PI3Kβ inhibitor AZD6482, and a cyclin-dependent kinase (CDK) 4/6 inhibitor PD-0332991, or palbociclib (Table 6; 0.348 ≤ ρ ≤ 0.405, padj ≤ 0.0436, n ≥ 100, Ntests = 26,610). This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.